Aldeyra Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Aldeyra Therapeutics

31/10/2024 03:30

* Aldeyra Therapeutics Inc  ALDX.OQ   ALDX.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 1 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Aldeyra Therapeutics Inc
is
for a loss of 25 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aldeyra
Therapeutics Inc is 10.00​, above​ its last closing price
of $5.34. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.14       -0.14      -0.28     Missed  -97.5
 Mar. 31 2024  -0.10       -0.11      -0.14     Missed  -26.5
 Dec. 31 2023  -0.05       -0.14      -0.08     Beat    43​
 Jan. 1 0001   -0.22       -0.24      -0.14     Beat    41.3
 ​​Jan.        -0.31       -0.31      -0.15     Beat    51.8
 1 0001                                                 
 Mar. 31 2023  -0.29       -0.29      -0.27     Beat    7.4​
 Dec. 31 2022  -0.29       -0.31      -0.22     Beat    29.7
 Jan. 1 0001   -0.33       -0.34      -0.25     Beat    27.3
 This summary was machine generated October 31 at 03:28 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)